Open-label, Phase II Study of MLN9708 in Patients With Relapsed/Refractory Cutaneous and Peripheral T-cell Lymphomas: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Open-label, Phase II Study of MLN9708 in Patients With Relapsed/Refractory Cutaneous and Peripheral T-cell Lymphomas (NCT02158975), a na phase 2 study. The primary outcome is Objective Response Rate.

2. Clinical Question

The study addressed whether MLN9708 showed activity in patients whose disease had relapsed or was refractory. The registry summary frames the rationale in relation to historical response rates with standard chemotherapy, but that background statement is not a concurrent comparison in this study. The design therefore concerns the observed response experience in the treated group rather than a randomized estimate of the difference between treatments.

The primary outcome was intended to capture response using a global composite scoring system across disease compartments. That approach is relevant to the question because the recorded definition considers clinical evidence of disease in skin, blood, lymph nodes, and viscera rather than describing a response in only one compartment. The registry record does not report the resulting objective response percentage, its confidence interval, or the response count. Consequently, the clinical question can be described from the protocol record, but its answer cannot be quantified from the posted results summarized in the record.

3. Trial Design

This was an open-label, single-center Phase II study of MLN9708 (ixazomib) for patients with relapsed or refractory cutaneous and peripheral T-cell lymphomas. The registry classifies it as a single-group study, with no allocation to a separate treatment arm and no masking. Enrollment is listed as 13. The primary-outcome population is described as 12 analyzable patients; the registry record does not explain the difference between those figures or give the criteria used to define analyzability.

MLN9708 was administered as 4mg by mouth weekly on days 1, 8, and 15 of every 28-day cycle. The primary outcome was objective response rate, defined through response in skin, blood, lymph nodes, and viscera using a global composite scoring system. The stated response categories were complete response, complete response unconfirmed, and partial response. The primary-outcome timeframe was up to 24 months after initiation of study treatment.

The study record lists secondary outcomes concerning adverse events of grades 3-5, median progression-free survival, median overall survival, and duration of response. It also describes an interest in GATA-3 expression, including whether that expression might be predictive of sensitivity to MLN9708. The record lists five outcome measures, but does not report results for the primary endpoint in the registry record for this analysis.

Study dates in the record are September 2014 for the start and October 2016 for primary completion, and the study status is completed. Completion of a study does not by itself establish that outcome estimates were posted. The registry record lists zero analyses, and it does not describe a randomized comparison or a comparator group. Results therefore need to be interpreted as a single-group record, not as a direct estimate of relative efficacy against another treatment.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: 12 analyzable patients

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Population: 12 analyzable patients

6. Primary Endpoint

The registry lists the primary outcome as Objective Response Rate, measured over Up to 24 months after initiation of study treatment.

The primary endpoint is objective response rate, expressed as the percentage of patients with an objective response. The registry defines response as complete response, complete response unconfirmed, or partial response. It describes a global composite scoring system that considers response in skin, blood, lymph nodes, and viscera. The timeframe is up to 24 months after initiation of study treatment.

A response proportion is a binary-outcome summary: each participant is classified according to whether the endpoint definition was met, and the proportion meeting it is reported for the stated analysis population. In general, this kind of endpoint gives a direct description of how often a prespecified response category was observed in the group being studied. A confidence interval adds information about the precision of that estimate; it conveys a range of values compatible with the data under the interval’s statistical assumptions. The registry specifies a 95% confidence interval for the primary measure, but the interval itself is not reported in the record details.

The endpoint is suited to describing observed tumor response in this study, but an objective response proportion alone does not describe the duration of response, progression-free survival, or overall survival. Those appear as separate secondary outcomes in the record. Nor does a response proportion from a single group estimate the treatment difference against a concurrent comparator. The registry record does not report the observed response percentage, its confidence interval, or the response count, so the endpoint’s actual result cannot be assessed from the reported information.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The registry identifies a percentage as the primary outcome and specifies a 95% confidence interval. It does not report the objective response estimate or the interval, and the statistical method used to calculate the interval is not reported in the registry record. The discussion below explains the general meaning of these methods without attributing an unreported analysis procedure to the study.

What does an objective response percentage describe?

For a binary endpoint, a participant either meets the stated response definition or does not. The response percentage summarizes the frequency of participants meeting that definition within the analysis population. Interpretation depends on the outcome definition and on which participants were included. In this study, the record defines response using complete response, complete response unconfirmed, or partial response, based on a global composite assessment across skin, blood, lymph nodes, and viscera.

A percentage is a compact description, but it should be read together with its denominator and the rules for classifying participants. The record says that 12 patients were analyzable for the primary outcome, but it does not provide the response count or explain how an unevaluable patient would be handled. The registry record also does not report assessment procedures, adjudication, or further details about the composite scoring implementation. Those omissions prevent a fuller assessment of how the endpoint was applied.

What does a confidence interval add?

In general, a confidence interval expresses the statistical uncertainty around an estimated quantity. It is not a guarantee that the true value lies within the particular interval, nor is it a measure of the clinical importance of an effect. A narrower interval generally indicates greater precision under the method’s assumptions; a wider interval indicates greater uncertainty. For a response percentage, the interval can help readers judge how much the estimate might vary because of sampling uncertainty.

The record specifies a 95% confidence interval but gives no interval endpoints and does not identify the calculation method. Different methods can behave differently, especially when samples are small or the event proportion is near an extreme. It would therefore be inappropriate to reconstruct an interval or claim that a particular method was used. The sponsor’s reported analysis, if available in another official result record, would take precedence over an unadjusted recalculation from summary data.

Why does the single-group design matter?

In general, an uncontrolled study estimates outcomes in the group observed under the study conditions. It cannot separate treatment effects from other explanations for observed outcomes, such as the course of disease, participant selection, assessment decisions, or other care. Open-label status means treatment assignment was not masked, and the registry lists no separate comparator group. This does not make a descriptive response proportion meaningless, but it does constrain the causal interpretation of that proportion.

The historical response rate discussed in the study rationale does not provide the same basis for comparison as a concurrent control group. Differences in populations, response definitions, follow-up, and assessment can make historical comparisons difficult to interpret. The registry does not report a prespecified comparative analysis against historical controls, so none should be inferred from the background statement.

How should the planning illustrations be read?

The planning assumptions describe an illustration based on the observed effect, with a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation. They are not a report of the trial’s own design: the study is recorded as single-group. The assumptions also describe detecting a stated fraction of an observed effect. Such calculations are hypothetical planning aids and should not be interpreted as the study’s achieved power or as evidence that the trial was designed with those parameters.

In general, power calculations depend on assumptions about the effect to detect, variability or event frequency, significance level, allocation, and analysis method. Changing those assumptions changes the planning result. A calculation based on an observed effect is particularly dependent on the uncertainty and possible exaggeration of that estimate. Since the registry record does not report the primary effect estimate, the planning illustrations cannot be independently evaluated from the information.

Why can event proportions be over-dispersed?

For binary outcomes, basic models often treat observations as independent and assume a common underlying event probability. In general, over-dispersion means the observed variability exceeds what that model expects. It can arise when participants differ in risk or when outcomes are clustered, and ignoring it can make uncertainty estimates too optimistic. The record does not report an over-dispersion assessment or a model for the primary endpoint. This explanation is general and does not imply that over-dispersion was present or that a particular model was used in this study.

The registry record lists zero analyses. It does not report the specific estimator, confidence-interval method, covariate adjustment, analysis software, or any model checks. Consequently, the appropriate reading is limited to the endpoint and design stated in the record, rather than an assumption about unreported statistical procedures.

10. Exact Estimates for Each Arm

No two-arm comparison is shown for this trial, but each arm's result can still be summarized with exact interval estimates computed from the posted counts. The Clopper-Pearson interval is exact and conservative; the Wilson interval is a common closer-to-nominal alternative; the Bayesian credible interval uses a uniform Beta(1, 1) prior. For small groups the three can differ noticeably.

R code and output

arm    <- c("MLN9708")
n      <- c(12)
events <- c(1)
for (i in seq_along(n)) {
  ci <- binom.test(events[i], n[i])$conf.int          # Clopper-Pearson exact interval
  cr <- qbeta(c(0.025, 0.975), 1 + events[i], 1 + n[i] - events[i])   # Bayesian, uniform Beta(1,1) prior
  wi <- (function(x, n) { p <- x / n; z <- qnorm(0.975); d <- 1 + z^2 / n
    c((p + z^2 / (2 * n) - z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d, (p + z^2 / (2 * n) + z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d) })(events[i], n[i])
  cat(sprintf("ARM|%s|%d|%d|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f\n", arm[i], n[i], events[i], 100 * events[i] / n[i],
              100 * ci[1], 100 * ci[2], 100 * wi[1], 100 * wi[2], 100 * cr[1], 100 * cr[2]))
}

ARM  MLN9708  12  1  8.3  0.2  38.5  1.5  35.4  1.9  36.0

11. Multiplicity, Missing Data and Analysis Populations

The registry record lists a primary objective response endpoint and secondary outcomes concerning adverse events of grades 3-5, median progression-free survival, median overall survival, and duration of response. It also describes an interest in GATA-3 expression and its possible predictive role. Considering multiple outcomes raises a general multiplicity issue: when many hypotheses are tested, the chance of at least one apparently notable result can increase. A statistical plan may address this by defining a primary hypothesis, controlling error rates, or treating secondary analyses as exploratory. The registry record does not report a multiplicity strategy, hierarchy, or adjustment.

The record specifies a 95% confidence interval for the primary endpoint but does not give the interval or its calculation method. It does not describe interim analyses, a statistical analysis plan, or how outcome data were to be handled when missing. Each of these items is not reported in the registry record. No approach to missing data, censoring, or sensitivity analysis should be inferred from the outcome descriptions alone.

Enrollment is listed as 13, while the primary population is described as 12 analyzable patients. The record does not explain the difference, define analyzability, or say whether any participant lacked a response assessment. The safety group lists 12 at risk. The relationship between these population descriptions is not reported in the registry record.

These uncertainties matter because analysis populations and missing-data rules affect the interpretation of a response percentage and its precision. The registry lists zero analyses and does not provide the primary result, so neither the handling of missing outcomes nor the application of multiplicity procedures can be evaluated.

12. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: acute kidney injury (8.3%), anemia (8.3%), atrial fibrillation (8.3%), diarrhea (8.3%), dyspnea (8.3%).

The safety record lists 12 patients at risk for serious adverse events and 8 affected, and 12 at risk for other adverse events and 10 affected. It also lists 1 death. These are separate reported counts; the record does not say whether the same patients contributed to both adverse-event categories or whether the death occurred among those with a reported event.

The serious adverse-event terms listed are acute kidney injury, anemia, atrial fibrillation, diarrhea, dyspnea, and hypercalcemia. Each term is reported at 8.3%. The record does not provide event counts by term, timing, severity details, recurrence, or treatment attribution in the registry record. The percentages should therefore be read as the registry’s reported frequencies, not as evidence about cause or about whether events overlapped.

A serious adverse event is a safety classification and is not interchangeable with an adverse event of a particular grade. The secondary-outcome list separately refers to adverse events of grades 3-5, while the safety counts identify serious events and other events. The record does not explain the relationship between those categories. The death count alone does not establish that treatment caused the death. These figures describe reported safety information; they do not support medical advice or a comparative safety conclusion.

13. What the Result Does, and Does Not, Mean

The record establishes that a completed, open-label, single-center Phase II study evaluated MLN9708 in patients with relapsed or refractory cutaneous and peripheral T-cell lymphomas. It specifies a single-group design, the treatment schedule, an objective response endpoint, and selected safety counts. This information helps readers understand what the study was intended to assess and how the registry characterizes its population and outcomes.

The primary result itself is not reported in the registry information available for this analysis. There is no objective response percentage, response count, or confidence interval to interpret. Accordingly, the record does not show the observed magnitude or precision of the primary outcome. That absence should not be mistaken for a zero response result, and it does not establish that no analysis was performed outside the registry record.

The study also does not provide a randomized comparison. A response percentage, if reported, would describe outcomes in the analyzed group and would not by itself establish a causal advantage over another treatment. Historical response rates in the rationale are background information rather than a concurrent control. The record’s listed secondary outcomes likewise cannot be interpreted without their results and analysis details.

The safety counts indicate that serious and other adverse events were reported among patients at risk, and the record lists a death. They do not establish whether events were caused by MLN9708, whether categories overlapped, or how risk compares with another treatment. The difference between enrollment and the primary analyzable population is not explained, limiting assessment of the outcome denominator and missingness.

Statistically, the most defensible conclusion is about the limits of the available evidence: the study design and endpoint are described, but the primary efficacy estimate is absent from the registry record. The record can support a description of study conduct and selected safety reporting, not a conclusion about treatment efficacy or comparative benefit.

14. Why This Trial Matters Statistically

This study is statistically informative as an example of the distinction between a clearly described endpoint and an interpretable result. The registry defines objective response, gives the response categories, identifies the disease compartments included in the composite assessment, and specifies a 95% confidence interval. Yet the response percentage and interval are not reported in the record details. A planned endpoint cannot substitute for its observed estimate.

The single-group, open-label design makes the distinction between description and comparison especially important. A response proportion can summarize what was recorded in the treated group, but without a concurrent control it cannot directly estimate a treatment contrast. The historical rate mentioned in the study rationale should not be treated as if it were a randomized comparator. This distinction applies broadly to early-phase clinical research, where descriptive evidence may be valuable while still carrying limits on causal interpretation.

The record also illustrates why population definitions belong alongside outcome summaries. Enrollment is listed as 13, while the primary outcome describes 12 analyzable patients. Because the registry does not explain that difference or define analyzability, readers cannot fully assess the denominator or determine how missing assessments may have affected the result. Reporting participant flow and analysis populations clearly is important for judging both possible bias and precision.

Finally, the safety record contains counts and listed serious-event terms, but does not establish causation or comparative risk. Separating event frequency, severity, seriousness, and attribution is essential to careful interpretation. Together, these features show why statistical reading requires more than identifying an endpoint: design, analysis population, uncertainty, missingness, and the completeness of posted results all shape what can be concluded.

15. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The record does not report the primary objective response result or its 95% confidence interval. It therefore does not permit assessment of the response frequency or its precision. The registry lists zero analyses, and the statistical method for the primary endpoint is not reported in the registry record.

The study is recorded as open-label, single-center, and single-group, with no separate comparator. Consequently, results from the treated group would not provide a randomized treatment contrast. The historical response rate in the rationale is not a concurrent control and cannot resolve that limitation.

Enrollment is listed as 13, whereas the primary outcome specifies 12 analyzable patients. The reason for this difference, the definition of analyzability, and the handling of missing or unevaluable response assessments are not reported in the registry record. The safety counts also list 12 at risk, but the record does not clarify how that population relates to the primary analysis population.

The response endpoint uses a global composite assessment across skin, blood, lymph nodes, and viscera. The record provides response categories but does not report further details about assessment procedures, independent review, or component-level results. The stated timeframe is up to 24 months after treatment initiation, but the record does not provide actual follow-up distributions or endpoint results.

Safety information is limited to counts and selected serious-event terms. The record does not report treatment attribution, event-level timing, overlap between categories, or a comparative safety estimate. These limitations are specific to the information recorded for this study; they do not establish that unreported procedures or analyses did not occur.

16. Related Tutorials

17. Related Statistical Calculators

18. Sources

• ClinicalTrials.gov: Open-label, Phase II Study of MLN9708 in Patients With Relapsed/Refractory Cutaneous and Peripheral T-cell Lymphomas — NCT02158975.
• Registry record last updated 2017-11-13; status last verified 2017-10.
• Results first posted 2017-11-13.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

19. Record Summary

The registry describes an open-label, single-center Phase II study of MLN9708 (ixazomib) in patients with relapsed or refractory cutaneous and peripheral T-cell lymphomas. It is classified as a single-group study, with no masking or separate comparator. The recorded regimen was 4mg by mouth weekly on days 1, 8, and 15 of every 28-day cycle.

The primary endpoint was objective response rate, based on complete response, complete response unconfirmed, or partial response across skin, blood, lymph nodes, and viscera. The record lists enrollment as 13 and the primary population as 12 analyzable patients. It does not report the primary response result or its confidence interval. Safety information includes 8 patients with serious adverse events, 10 with other adverse events, and 1 death among the listed at-risk group of 12. The study status is completed; the registry record does not report the analysis details needed to resolve the primary outcome.